SCYNEXIS, Inc

SCYNEXIS, Inc. is a U.S.-based biopharmaceutical company focused on developing antifungal medicines for serious and drug-resistant fungal infections. Its core platform, called fungerps, includes ibrexafungerp and the follow-on candidate SCY-247, with development, licensing, and commercialization activities centered on human health applications.

−41,8 %

+449,9 %

7.04

7.04

— SCYNEXIS, Inc
%
Approved antifungal product5% Commercialized ibrexafungerp-based therapy marketed as BREXAFEMME for vaginal fungal infections.
Clinical-stage antifungal candidates55% SCY-247 and other pipeline compounds being developed for difficult-to-treat fungal infections.
License and royalty revenue40% Revenue from licensing arrangements and milestone/royalty economics tied to partnered assets.

SCYNEXIS sells into the human-health pharmaceutical market rather than to end consumers directly, so its customers...

  • Licensing partnersprimary

    Pharmaceutical companies such as GSK and other collaborators that pay for rights, milestones, and royalties.

  • Healthcare providersprimary

    Hospitals, specialists, and prescribers that use antifungal therapies in clinical settings.

  • Patients with fungal infectionsprimary

    Patients treated for vulvovaginal candidiasis, recurrent infections, or severe systemic fungal disease.

  • Third-party payorssecondary

    Commercial insurers and government programs that determine coverage and reimbursement.

SCYNEXIS is headquartered in the United States and conducts its core research, development, and corporate activities...

  • •United States is the main operating base for R&D and corporate functions
  • •GSK Territory drives partnered commercialization outside the core U.S. setup
  • •China rights are licensed through Hansoh for ibrexafungerp
  • •Russia and several non-core markets are licensed to R-Pharm
  • •International partners create royalty exposure across multiple jurisdictions

SCYNEXIS is focused on advancing SCY-247 through clinical development while using its partnered assets to generate...

01
Complete SCY-247 clinical development milestonesshort-term

Clinical progress is the main driver of future value creation for the pipeline.

02
Monetize partnered assets through royalties and milestonesshort-term

Partner economics can fund operations without relying entirely on new equity.

03
Expand the antifungal portfolio through in-licensingmedium-term

Additional assets can diversify scientific risk and create future commercialization options.

SCYNEXIS faces the typical risks of a development-stage biopharmaceutical company: clinical failure, regulatory delay,...

high

Clinical development failure for SCY-247

The lead pipeline asset is still in development and may not show adequate safety or efficacy.

Scope
SCY-247 and future fungerp candidates
Materiality
high
high

Regulatory approval and timing risk

Drug candidates require successful FDA and other regulatory reviews before commercialization.

Scope
SCY-247, future pipeline assets
Materiality
high
high

Manufacturing and supply chain dependence

The company relies on third-party CMOs and suppliers for drug product and clinical supply.

Scope
SCY-247 and licensed products
Materiality
high
medium

Reimbursement and market access pressure

Coverage decisions by payors can determine whether branded antifungals gain adoption.

Scope
BREXAFEMME and future commercial products
Materiality
medium
medium

Competition from generic and established antifungals

Existing therapies are widely available and may be cheaper or more familiar to prescribers.

Scope
Antifungal treatment market
Materiality
medium
License agreement revenue recognition
Can cause lumpy quarterly revenue and affect comparability
Research and development expense estimation
Affects reported operating loss and period timing
Stock-based compensation
Impacts SG&A and R&D expense trends
Contingencies and litigation
Could affect liabilities and future cash outflows

SCYNEXIS INC

SCYX · Pharmaceutical Preparations

SOLIGENIX, INC.

SNGX · Pharmaceutical Preparations

Sionna Therapeutics, Inc.

SION · Pharmaceutical Preparations

ZYNEX INC

ZYXIQ · Electromedical & Electrotherapeutic Apparatus

IONIS PHARMACEUTICALS INC

IONS · Pharmaceutical Preparations

NEUROCRINE BIOSCIENCES INC

NBIX · Biological Products, (No Diagnostic Substances)

: 29.4.2026